Format

Send to:

Choose Destination
See comment in PubMed Commons below
Infection. 2014 Aug;42(4):757-62. doi: 10.1007/s15010-014-0630-4. Epub 2014 Jun 6.

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.

Collaborators (213)

Losso M, Kundro M, Vetter N, Zangerle R, Karpov I, Vassilenko A, Mitsura VM, Suetnov O, De Wit S, Delforge M, Colebunders R, Vandekerckhove L, Hadziosmanovic V, Kostov K, Begovac J, Machala L, Jilich D, Sedlacek D, Nielsen J, Kronborg G, Benfield T, Larsen M, Gerstoft J, Katzenstein T, Hansen AB, Skinhøj P, Pedersen C, Ostergaard L, Zilmer K, Ristola M, Katlama C, Viard JP, Girard PM, Livrozet JM, Vanhems P, Pradier C, Dabis F, Neau D, Rockstroh J, Schmidt R, van Lunzen J, Degen O, Stellbrink HJ, Bickel MM, Goethe JW, Bogner J, Fätkenheuer G, Kosmidis J, Gargalianos P, Xylomenos G, Perdios J, Panos G, Filandras A, Karabatsaki E, Sambatakou H, Banhegyi D, Mulcahy F, Yust I, Turner D, Pollack S, Hassoun G, Maayan S, Vella S, Esposito R, Mazeu I, Mussini C, Arici C, Pristera R, Mazzotta F, Gabbuti A, Vullo V, Lichtner M, Chirianni A, Montesarchio E, Gargiulo M, Cotugno AD, Antonucci G, Testa A, D'Offizi G, Vlassi C, Zaccarelli M, Antorini A, Lazzarin A, Castagna A, Gianotti N, Galli M, Ridolfo A, Sacco L, Rozentale B, Zeltina I, Chaplinskas S, Staub T, Hemmer R, Reiss P, Ormaasen V, Maeland A, Bruun J, Knysz B, Gasiorowski J, Horban A, Bakowska E, Grzeszczuk A, Flisiak R, Boron-Kaczmarska A, Pynka M, Parczewski M, Beniowski M, Mularska E, Trocha H, Jablonowska E, Malolepsza E, Wojcik K, Antunes F, Doroana M, Caldeira L, Mansinho K, Maltez F, Duiculescu D, Babes V, Rakhmanova A, Zakharova N, Buzunova S, Jevtovic D, Mokráš M, Staneková D, Tomazic J, González-Lahoz J, Soriano V, Labarga P, Medrano J, Moreno S, Rodriguez J, Clotet B, Jou A, Paredes R, Tural C, Puig J, Bravo I, Gatell JM, Miro JM, Domingo P, Gutierrez M, Mateo G, Sambeat MA, Blaxhult A, Flamholc L, Thalme A, Sonnerborg A, Ledergerber B, Weber R, Francioli P, Cavassini M, Hirschel B, Boffi E, Furrer H, Battegay M, Elzi L, Kravchenko E, Chentsova N, Frolov V, Kutsyna G, Servitskiy S, Krasnov M, Barton S, Johnson AM, Mercey D, Phillips A, Johnson MA, Mocroft A, Murphy M, Weber J, Scullard G, Fisher M, Leen C, Gatell J, Gazzard B, Horban A, Karpov I, Ledergerber B, Losso M, D'Arminio Monforte A, Pedersen C, Rakhmanova A, Ristola M, Rockstroh J, De Wit S, Lundgren J, Phillips A, Reiss P, Kirk O, Mocroft A, Cozzi-Lepri A, Grint D, Schultze A, Shepherd L, Sabin M, Podlekareva D, Kjær J, Peters L, Nielsen J, Tverland J, Fischer AH, Kirk O, Mocroft A, Grarup J, Reiss P, Cozzi-Lepri A, Thiebaut R, Rockstroh J, Burger D, Paredes R, Kjær J, Peters L.

Abstract

ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

PMID:
24902520
[PubMed - indexed for MEDLINE]
PMCID:
PMC4103996
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk